BioNTech SE (BNTX) shares surged 5.32% in pre-market trading on Tuesday, following the announcement of a major research and development partnership with the UK government. The company plans to invest up to £1 billion ($1.33 billion) over 10 years to expand its research operations in the UK, supported by a government grant of up to £129 million.

The deal includes plans to open two new research centers and establish a headquarters in London. BioNTech aims to accelerate clinical trials, expand research areas, and grow its artificial intelligence hub. This significant investment demonstrates the company's commitment to long-term growth and innovation in the biotech sector.

Adding to the positive sentiment, reports of rising Covid-19 cases in several Asian countries, including Singapore, Hong Kong, and Thailand, have sparked speculation about potential increased demand for vaccines. As a leading Covid-19 vaccine developer, BioNTech stands to benefit from any resurgence in global vaccine requirements. Investors appear optimistic about the company's prospects in both its expanded research initiatives and potential renewed demand for its core product.